Business Description
Ocuphire Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US67577R1023
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.67 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 50.5 | |||||
3-Year EPS without NRI Growth Rate | 49 | |||||
3-Year FCF Growth Rate | 67.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 74.55 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.21 | |||||
9-Day RSI | 57.26 | |||||
14-Day RSI | 51.3 | |||||
6-1 Month Momentum % | -39.8 | |||||
12-1 Month Momentum % | -69.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.68 | |||||
Quick Ratio | 10.68 | |||||
Cash Ratio | 9.87 | |||||
Days Sales Outstanding | 64.24 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.1 | |||||
Shareholder Yield % | -11.06 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -91.67 | |||||
Net Margin % | -85.75 | |||||
FCF Margin % | -69.59 | |||||
ROE % | -31.4 | |||||
ROA % | -28.41 | |||||
ROIC % | -760.75 | |||||
3-Year ROIIC % | -1849.46 | |||||
ROC (Joel Greenblatt) % | -681.26 | |||||
ROCE % | -33.97 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 9.04 | |||||
PS Ratio | 1.92 | |||||
PB Ratio | 0.88 | |||||
Price-to-Tangible-Book | 0.83 | |||||
EV-to-EBIT | 0.49 | |||||
EV-to-Forward-EBIT | -2.42 | |||||
EV-to-EBITDA | 0.49 | |||||
EV-to-Forward-EBITDA | 1.49 | |||||
EV-to-Revenue | -0.46 | |||||
EV-to-Forward-Revenue | 0.2 | |||||
EV-to-FCF | 0.46 | |||||
Price-to-Net-Current-Asset-Value | 0.83 | |||||
Price-to-Net-Cash | 0.9 | |||||
Earnings Yield (Greenblatt) % | 204.55 | |||||
FCF Yield % | -34.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ocuphire Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 15.341 | ||
EPS (TTM) (€) | -0.505 | ||
Beta | 0.83 | ||
Volatility % | 57.44 | ||
14-Day RSI | 51.3 | ||
14-Day ATR (€) | 0.060079 | ||
20-Day SMA (€) | 1.0855 | ||
12-1 Month Momentum % | -69.79 | ||
52-Week Range (€) | 0.98 - 4.37 | ||
Shares Outstanding (Mil) | 26.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ocuphire Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ocuphire Pharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ocuphire Pharma Inc Frequently Asked Questions
What is Ocuphire Pharma Inc(FRA:R3X1)'s stock price today?
When is next earnings date of Ocuphire Pharma Inc(FRA:R3X1)?
Does Ocuphire Pharma Inc(FRA:R3X1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |